Nephrotoxicity of vemurafenib and babrafenib, particularly in male patients with BRAF mutation positive melanoma

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

The BRAF inhibitors vemurafenib and dabrafenib have shown significant improvement in patient survival compared with standard therapy in BRAF V600-mutant metastatic melanoma. Results suggest vemurafenib seems to be more nephrotoxic than dabrafenib and renal toxicity seems to be more prevalent among male patients with melanoma. Dermatologists, oncologists, and nephrologists need to be aware of this potential hazard.


  • Review of FDA Adverse Event Reporting System (FAERS) data for both agents for renal toxic effects


  • From July 2011 through June 2...